Sanofi 20262027 Flu Vaccines
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
ACQUISITIONS - AQM MOMENTUM
Contract Value
Not provided
Codes & Classification
Solicitation Number
19AQMM26F1490
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents1
The U.S. Department of State, through its Acquisitions - AQM Momentum office, has issued a justification notice for the procurement of Sanofi’s Fluzone and Flublok influenza vaccines for the 2026-2027 flu season. This procurement is specifically intended to support the immunization of immunocompromised family members associated with U.S. embassies, underscoring the critical importance of safeguarding vulnerable populations within diplomatic communities.
The scope of this activity centers on the acquisition of pharmaceutical-grade influenza vaccines, manufactured by Sanofi, to ensure timely and effective immunization coverage. The expected outcome is the provision of high-quality, reliable vaccines that meet the unique health requirements of immunocompromised individuals, thereby reducing the risk of influenza-related complications and supporting the overall health and safety of embassy families.
Key requirements include the supply of Fluzone and Flublok vaccines, both recognized for their efficacy in preventing influenza. The deliverables are clearly defined as the provision of these vaccines for the specified flu season, with the place of performance designated as Swiftwater, Pennsylvania, which is a known location for Sanofi’s vaccine manufacturing operations.
This procurement falls under NAICS code 325412 (Pharmaceutical Preparation Manufacturing), with the relevant product service code being 6505. The contracting entity is a federal office within the Department of State, and the primary point of contact for this opportunity is Lesley A. Stewart, who can be reached at [email protected] for further information.
The notice is classified as a justification, indicating that the Department of State has determined a specific need for these vaccines, likely due to their suitability for immunocompromised individuals and the critical nature of embassy health programs. No set-aside requirements or special considerations are specified in the notice, and the procurement is active as of October 21, 2026.
Contractors interested in this opportunity should note the focus on pharmaceutical manufacturing capabilities, particularly in the production and supply of influenza vaccines suitable for immunocompromised populations. The requirements and objectives are expected to remain constant throughout the contract lifecycle, emphasizing the need for consistent quality, reliability, and compliance with federal health standards.
For additional details and to review the official notice, contractors may visit the SAM.gov opportunity page at https://sam.gov/opp/3b3938d3903047c3a5c5d497dc988711/view.